Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy
Publication type: Journal Article
Publication date: 2017-08-01
scimago Q1
wos Q1
SJR: 2.756
CiteScore: 13.9
Impact factor: 10.1
ISSN: 03043835, 18727980
PubMed ID:
28536009
Cancer Research
Oncology
Abstract
Melittin (MEL), a major peptide component of bee venom, is an attractive candidate for cancer therapy. This agent has shown a variety of anti-cancer effects in preclinical cell culture and animal model systems. Despite a convincing efficacy data against variety of cancers, its applicability to humans has met with challenges due to several issues including its non-specific cytotoxicity, degradation and hemolytic activity. Several optimization approaches including utilization of nanoparticle based delivery of MEL have been utilized to circumvent the issues. Here, we summarize the current understanding of the anticancer effects of bee venom and MEL on different kinds of cancers. Further, we also present the available information for the possible mechanism of action of bee venom and/or MEL.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
2
4
6
8
10
12
14
|
|
|
Toxins
13 publications, 4.35%
|
|
|
Toxicon
7 publications, 2.34%
|
|
|
Pharmaceutics
6 publications, 2.01%
|
|
|
International Journal of Molecular Sciences
6 publications, 2.01%
|
|
|
International Journal of Peptide Research and Therapeutics
6 publications, 2.01%
|
|
|
Molecules
5 publications, 1.67%
|
|
|
Antibiotics
5 publications, 1.67%
|
|
|
Cancers
4 publications, 1.34%
|
|
|
Frontiers in Pharmacology
4 publications, 1.34%
|
|
|
Scientific Reports
4 publications, 1.34%
|
|
|
Journal of Controlled Release
4 publications, 1.34%
|
|
|
Biomedicine and Pharmacotherapy
4 publications, 1.34%
|
|
|
Journal of Drug Delivery Science and Technology
4 publications, 1.34%
|
|
|
ACS applied materials & interfaces
4 publications, 1.34%
|
|
|
Toxin Reviews
3 publications, 1%
|
|
|
Oxidative Medicine and Cellular Longevity
3 publications, 1%
|
|
|
International Journal of Biological Macromolecules
3 publications, 1%
|
|
|
Biochemical Society Transactions
2 publications, 0.67%
|
|
|
Biomolecules
2 publications, 0.67%
|
|
|
Frontiers in Microbiology
2 publications, 0.67%
|
|
|
Frontiers in Oncology
2 publications, 0.67%
|
|
|
Nature Communications
2 publications, 0.67%
|
|
|
Applied Microbiology and Biotechnology
2 publications, 0.67%
|
|
|
PLoS ONE
2 publications, 0.67%
|
|
|
European Journal of Pharmaceutical Sciences
2 publications, 0.67%
|
|
|
Biomaterials
2 publications, 0.67%
|
|
|
Bioorganic Chemistry
2 publications, 0.67%
|
|
|
Advanced healthcare materials
2 publications, 0.67%
|
|
|
Journal of Physical Chemistry B
2 publications, 0.67%
|
|
|
2
4
6
8
10
12
14
|
Publishers
|
10
20
30
40
50
60
70
80
|
|
|
Elsevier
76 publications, 25.42%
|
|
|
MDPI
50 publications, 16.72%
|
|
|
Springer Nature
41 publications, 13.71%
|
|
|
Wiley
22 publications, 7.36%
|
|
|
Taylor & Francis
22 publications, 7.36%
|
|
|
Frontiers Media S.A.
16 publications, 5.35%
|
|
|
American Chemical Society (ACS)
16 publications, 5.35%
|
|
|
Bentham Science Publishers Ltd.
7 publications, 2.34%
|
|
|
Hindawi Limited
6 publications, 2.01%
|
|
|
Royal Society of Chemistry (RSC)
5 publications, 1.67%
|
|
|
SAGE
3 publications, 1%
|
|
|
IntechOpen
3 publications, 1%
|
|
|
Portland Press
2 publications, 0.67%
|
|
|
Public Library of Science (PLoS)
2 publications, 0.67%
|
|
|
Spandidos Publications
2 publications, 0.67%
|
|
|
American Society for Biochemistry and Molecular Biology
1 publication, 0.33%
|
|
|
Huazhong University of Science and Technology
1 publication, 0.33%
|
|
|
King Saud University
1 publication, 0.33%
|
|
|
Asian Network for Scientific Information
1 publication, 0.33%
|
|
|
Walter de Gruyter
1 publication, 0.33%
|
|
|
Turkish Chemical Society
1 publication, 0.33%
|
|
|
Bursa Uludag University
1 publication, 0.33%
|
|
|
Korean Society for Biochemistry and Molecular Biology - BMB Reports
1 publication, 0.33%
|
|
|
Zhejiang University Press
1 publication, 0.33%
|
|
|
Impact Journals
1 publication, 0.33%
|
|
|
Bashkir State Medical University
1 publication, 0.33%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 0.33%
|
|
|
Medknow
1 publication, 0.33%
|
|
|
American Physical Society (APS)
1 publication, 0.33%
|
|
|
10
20
30
40
50
60
70
80
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
300
Total citations:
300
Citations from 2024:
96
(32.11%)
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Rady I. et al. Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy // Cancer Letters. 2017. Vol. 402. pp. 16-31.
GOST all authors (up to 50)
Copy
Rady I., Siddiqui I. A., Rady M., Mukhtar H. Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy // Cancer Letters. 2017. Vol. 402. pp. 16-31.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.canlet.2017.05.010
UR - https://doi.org/10.1016/j.canlet.2017.05.010
TI - Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy
T2 - Cancer Letters
AU - Rady, Islam
AU - Siddiqui, Imtiaz A.
AU - Rady, Mohamad
AU - Mukhtar, Hasan
PY - 2017
DA - 2017/08/01
PB - Elsevier
SP - 16-31
VL - 402
PMID - 28536009
SN - 0304-3835
SN - 1872-7980
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2017_Rady,
author = {Islam Rady and Imtiaz A. Siddiqui and Mohamad Rady and Hasan Mukhtar},
title = {Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy},
journal = {Cancer Letters},
year = {2017},
volume = {402},
publisher = {Elsevier},
month = {aug},
url = {https://doi.org/10.1016/j.canlet.2017.05.010},
pages = {16--31},
doi = {10.1016/j.canlet.2017.05.010}
}